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Key Points
• PTEN is downregulated in
Se´zary syndrome by different
mechanisms, mostly by gene
deletions and microRNAs.
• PTEN deficiency activates
AKT in skin resident but not
circulating Sezary cells.
Se´zary syndrome (SS) is an incurable leukemic variant of cutaneous T-cell lymphoma
characterized by recurrent chromosomal alterations, among which, chromosome 10q
deletion is very frequent. In this study, we investigated the PTEN status, on locus
10q23, in 44 SS patients; our findings show that PTEN is deleted in 36% of SS cases,
whereas PTEN downregulation is observed in almost all of the samples evaluated by
quantitative reverse-transcriptase polymerase chain reaction and Western blotting
analysis. Neither DNA sequence mutation nor promoter hypermethylation were found
at the PTEN locus, but we demonstrate that PTEN level can be also reduced by
a group of miRs previously found upregulated and of prognostic relevance in SS;
particularly, miR-21, miR-106b, and miR-486 were able to control PTEN abundance
either in vitro or in vivo. Finally, because reduced PTEN activates the PI3/AKT-mediated pathway of cell growth and survival, we
demonstrate that PTEN deficiency is associated with activated AKT in skin resident but not circulating SS cells, suggesting that
the cutaneous milieu may strongly contribute to the SS cell growth. To our knowledge, this is the first study fully exploring the
PTEN status in a large cohort of SS patients, unveiling potential elements of clinical utility in this malignancy. (Blood. 2013;
122(20):3511-3520)
Introduction
Cutaneous T-cell lymphoma (CTCL) represents a malignant
expansion of CD41CD45RO1 memory lymphocytes that show
a strong propensity for the skin. The most aggressive entity of
CTCLs is Se´zary syndrome (SS), a leukemic variant characterized
by the presence of malignant lymphocytes named Sezary cells in
the skin, lymph nodes, and peripheral blood.1 Despite major
therapeutic advances during the last few years,2 SS remains
incurable and discovery of new compounds will require a better
understanding of the molecular mechanism driving SS cell sur-
vival and proliferation, as well as more speciﬁc targeting strate-
gies. Recently, studies using both high-density comparative genomic
hybridization (CGH) and single nucleotide polymorphism (SNP)
array technologies demonstrated that SS is characterized by
speciﬁc chromosomal gains and deletions. Among these, loss of
chromosome 10q, including the PTEN locus at 10q23, appears to
be particularly common in these individuals.3-5
PTEN is a nonredundant lipid phosphatase whose main role is
to antagonize the PI3K signaling,6 a relevant pathway for cancer
development with several members representing potential targets
for therapeutics.7 PTEN is one of the most frequently lost or
mutated genes in human cancers,8 including T-cell malignancies
as T-cell acute lymphoblastic leukemia9 and CTCL, as already
demonstrated by loss of heterozygosity (LOH) found within the
PTEN locus of mycosis fungoides (MF).10 PTEN plays a critical
role in T-cell development; in fact, conditional loss of PTEN in
thymocytes leads to T-cell lymphomas.11,12 Conversely, PTEN de-
letion in mature T-cell subsets induces autoimmunity, increased
cytokine releasing, and, in general, a PI3K/AKT hyperactivation
through T-cell receptor also in absence of CD28 co-stimulation, thus
indicating that PTEN imposes stringent environmental signals for an
appropriate T-cell activation.13
In addition to the mutations and genetic alterations, PTEN abun-
dance appears to be ﬁnely regulated at the transcriptional/translational
level by microRNAs (miRNAs),6 competitive endogenous pseudo-
gene RNAs,14 and promoter hypermethylation,15 and at the posttrans-
lational level by phosphorylation and ubiquitination.15 It has recently
been demonstrated that programmed death-1, a gene also found
overexpressed in SS,16 regulates the PTEN phosphatase activity
through these last regulatory mechanisms, thereby promoting or
inhibiting the PI3K/AKT signaling.17
Defects of all of these mechanism(s) may have critical conse-
quences for PTEN levels18,19 and tumorigenesis. Here, we investi-
gated the PTEN status and the mechanisms of its deregulation in
a cohort of 44 SS patients.
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Table 1. PTEN and PTENP1 genomic status and promoter methylation analysis
Copy number status of PTEN (10q23) and PTENP1 (9p13.3)
ID Diagnosis
Mapping
array
PTEN
locus
PTEN LOH
status UPD
PTEN promoter
methylation
Genomic
qRT-PCR
PTENP1
locus
PTENP1 LOH
status
PTENP1
UPD
02 T SS 10K ML 1 0 ND ND WT 0 0
05 T SS 10K WT 0 0 ND ND WT 0 0
08 T1 SS 10K WT 0 0 ND ND WT 0 0
08 T2 SS 10K/aCGH WT 0 0 ND ND WT 0 0
11 T SS 10K/aCGH WT 0 0 ND ND WT 0 0
15 T SS 10K/aCGH WT 0 0 ND ND WT 0 0
22 T SS 10K/aCGH ML 1 0 ND ND ML 1 0
23 T1 SS SNP 6.0 WT 0 0 U ND WT 0 0
23 T2 SS SNP 6.0 WT 0 0 ND ND WT 0 0
23 T3 SS SNP 6.0 WT 0 0 ND ND WT 0 0
25 T SS 10K/aCGH ML 0 0 ND ND WT 0 0
27 T SS 10K/aCGH WT 0 0 ND ND WT 0 0
28 T SS 10K/aCGH WT 1 1 U 0.61 WT 0 0
30 T1 SS 10K WT 0 0 U 1.13 WT 0 0
30 T2 SS 10K/aCGH WT 0 0 ND ND WT 0 0
32 T1 SS 10K/aCGH ML 1 0 U ND WT 0 0
32 T2 SS SNP 6.0 ML 1 0 ND 0.67 WT 0 0
33 T SS 10K/aCGH WT 0 0 ND ND WT 0 0
34 T SS 10K/aCGH WT 0 0 ND ND WT 0 0
35 T SS 10K/aCGH WT 0 0 ND ND WT 0 0
36 T SS 10K/aCGH ML 0 0 U 0.69 WT 0 0
37 T SS 10K/aCGH WT 0 0 ND ND WT 0 0
38 T1 SS 10K/aCGH WT 0 0 ND ND WT 0 0
38 T2 SS 10K WT 0 0 ND ND WT 0 0
38 T3 SS SNP 6.0 WT 0 0 ND 1,01 WT 0 0
39 T1 SS 10K/aCGH ML 1 0 U 0.43 WT 0 0
39 T2 SS SNP 6.0 ML 0 0 ND ND WT 0 0
40 T1 SS 10K WT 0 0 U 0.86 WT 0 0
40 T2 SS 10K WT 0 0 ND ND WT 0 0
40 T3f SS 10K WT 0 0 ND ND WT 0 0
41 T1 SS 10K WT 0 0 U 1.19 WT 0 0
41 T2 SS 10K/aCGH WT 0 0 ND ND WT 0 0
41 T3 SS SNP 6.0 WT 0 0 ND ND WT 0 0
42 T1 SS 10K/aCGH ML 0 0 ND ND WT 0 0
43 T1 SS 10K WT 0 0 ND ND WT 0 0
43 T2 SS 10K/aCGH WT 0 0 U 0.85 WT 0 0
43 T3 SS SNP 6.0 WT 0 0 U 1.09 WT 0 0
44 T1 SS 10K WT 0 0 ND ND WT 0 0
45 T1 SS 10K/aCGH WT 0 0 U 1.07 WT 0 0
45 T2 SS SNP 6.0 WT 0 0 ND 0.72 WT 0 0
46 T1 SS 10K WT 0 0 ND ND WT 0 0
48 T1 SS 10K/aCGH ML 1 0 ND 0.45 ML 1 0
49 T1 SS 10K/aCGH ML 0 0 ND ND WT 0 0
50 T1 SS SNP 6.0 WT 0 0 U ND WT 0 0
50 T2 SS 10K WT 0 0 ND 1.06 WT 0 0
51 T1 SS 10K/aCGH WT 0 0 U 1.20 WT 0 0
53 T1 SS SNP 6.0 ML 0 0 U ND ML 0 0
53 T2 SS SNP 6.0 ML 0 0 ND 0.49 ML 0 0
55 T1 SS 10K ML 1 0 U 0.50 WT 0 0
57 T1 SS SNP 6.0 ML 1 0 ND 0.30 WT 0 0
58 T1 SS 10K ML 0 0 U 0.44 WT 0 0
60 T1 SS SNP 6.0 WT 0 0 U ND WT 0 0
60 T2 SS SNP 6.0 WT 0 0 U 1.20 WT 0 0
61 T1 SS 10K ML 0 0 ND ND WT 0 0
61 T2 SS 10K BL 0 0 PCR failed 0.09 WT 0 0
62 T1 SS 10K WT 0 0 U 1.17 WT 0 0
63 T1 SS SNP 6.0 WT 0 0 U 1.06 WT 0 0
63 T2 SS SNP 6.0 WT 0 0 ND ND WT 0 0
64 T1 SS SNP 6.0 ML 0 0 U 0.51 WT 0 0
64 T2 SS SNP 6.0 BL 0 0 ND 0.26 WT 0 0
0, absent; 1, present; BL, biallelic loss; M, methylated; ML, monoallelic loss; ND, not determined; U, unmethylated; WT, diploid.
Bold denotes SS patients derived from the data set already published in Caprini et al.5
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Methods
Patients, tumor, normal cells isolation, and genomic
DNA extraction
SS patients were enrolled in this study approved by the Ethical Committee
of the Istituto Dermopatico dell’Immacolata, and informed consent was
obtained in accordance with the Declaration of Helsinki. Diagnosis of SS
was based on the described criteria.20 The major clinical and immunologic
characteristics are reported in supplemental Table 1 on the Blood Web site.
Tumor, normal cell isolation, and genomic DNA extraction was per-
formed as described elsewhere.5
Reagents
Hut78 (TIB161), its clonal derivative H9 (HTB 176), and HH (CRL2105)
cell lines from American Type Culture Collection (ATCC, Manassas, VA)
established from the peripheral blood of CTCL patients were grown in
complete RPMI 1640 supplemented with 10% fetal bovine serum (Sigma-
Aldrich, St. Louis, MO)
Primers for quantitative RT-PCR (qRT-PCR) and DNA methylation
analysis were designed using Primer3 Input 0.4.0 and synthesized by Euroﬁns
MWG Operon. Primer sequences are shown in supplemental Table 2.
DNA methylation analysis
In total, 200 ng of genomic DNA from each sample was treated with
a Methylamp DNA modiﬁcation sample kit (Epigentek, Brooklyn, NY) to
convert the unmethylated cytosine to uracil according to the manufacturer’s
instructions. CpGenome Universal Methylated DNA was included as a
methylated genomic DNA control (Millipore, Billerica, MA). Bisulﬁte-
treated DNA was analyzed by PCR with methylated or unmethylated
speciﬁc primers designed outside the common region between PTEN and
the homolog pseudogene PTENP1.8 PCR products were separated by 2%
agarose gel electrophoresis and visualized with ethidium bromide staining.
Genomic RT-PCR analysis
Genomic qRT-PCR was performed on the DNA of 27 SS samples using the
GoTaq qPCR Master MIX (Promega) on an ABI PRISM 7000 Sequence
Detection System (Applied Biosystems). We used the method described by
Hoebeeck et al.21 Brieﬂy, 2 endogenous controls (SDC4, COMT) not af-
fected by copy-number changes were used for normalization of qRT-PCR
data; the fold change (FC) values were calculated using an Affymetrix
genomic DNA reference diploid sample by the standard curve methods.
PTEN copy-number analysis
In total, 500 ng of genomic DNA was input for the Genome-Wide Human
SNP6.0 Array (Affymetrix, Santa Clara, CA), according to the manufacturer’s
speciﬁcations. CEL ﬁles were converted by Genotyping Console Software
to perform copy number and LOH analysis. Gains and losses were
summarized by the segment reporting tool and displayed in the genotyping
console browser. This browser aligns whole-genome to annotated genes
and copy-number variations, ﬂuorescence in situ hybridization clones, or
customized tracks.
PTEN sequencing
PTEN coding sequence (accession number NM_000314.4) and the 4 regions
within 39UTR containing recognized miR-106b binding sites (2041-2566,
3135-3280, 3261-3419, 3634-3763) were sequenced. Primer pairs for the
ampliﬁcation of each region-of-interest were designed using Ampliseq
Designer v.1.2.9 software (Life Technologies) (https://www.ampliseq.com/
browse.action). Sequence analysis was conducted using Torrent Suite from
Life Technologies. For library preparation, sequencing data analysis, and
variants identiﬁcation, see the supplemental Material and methods.
qRT-PCR
The RNA puriﬁcation by Trizol was performed according to the manu-
facturer’s indications (Invitrogen). Mature miRNAs were analyzed using the
TaqMan microRNA assay (Applied Biosystems), and Z30 was used as an
internal normalized reference.
PTEN and PTENP1 expression analysis was performed with a SYBR
Green I dye chemistry and AmpliTaq Gold DNA Polymerase on an ABI
PRISM 7000 machine (Applied Biosystems).
Quantitative gene expression analysis was performed by the DCT
method as described previously.22
Cell-line transfections
Pre-miRNAs (Ambion) and LNA knockdown oligos (Exiqon) were trans-
fected to H9 cells at the ﬁnal concentration of 100 nM by a Siport
transfection reagent (Ambion) following the manufacturer’s instructions.
Western blotting
Cells were lysed in a RIPA buffer supplemented with a phosphatase and
protease inhibitor cocktail (Roche Diagnostic, Indianapolis, IN). Proteins
were quantiﬁed using BCA protein assay (Bio-Rad, Hercules, CA) and
resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
probed using standard techniques.23 Membranes were probed with speciﬁc
primary antibodies for PTEN used 1:500, AKT used 1:2000, phospho-AKT
used 1:500 (Cell Signaling), and b-actin diluted 1:1000 (clone AC-40;
Sigma-Aldrich) used as an internal standard for loading. Immunodetection
was carried out by using appropriate horseradish peroxidase–linked secondary
antibodies and enhanced chemiluminescence detection reagents (GEHealthcare,
Amersham Biosciences, Little Chalfont, United Kingdom).)
Table 1. (continued).
Copy number status of PTEN (10q23) and PTENP1 (9p13.3)
ID Diagnosis
Mapping
array
PTEN
locus
PTEN LOH
status UPD
PTEN promoter
methylation
Genomic
qRT-PCR
PTENP1
locus
PTENP1 LOH
status
PTENP1
UPD
65 T1 SS SNP 6.0 WT 0 0 U 1.20 WT 0 0
66 T1 SS 10K WT 0 0 ND ND WT 0 0
67 T1 SS SNP 6.0 ML 0 0 U 0.47 WT 0 0
69 T1 SS SNP 6.0 WT 0 0 ND ND WT 0 0
70 T1 SS SNP 6.0 WT 0 0 U ND WT 0 0
Hut78 Cell line SNP 6.0 ML 1 0 U ND ML 1 0
H9 Cell line SNP 6.0 ML 1 0 U ND ML 1 0
HH Cell line SNP 6.0 BL 0 0 U ND WT 0 0
0, absent; 1, present; BL, biallelic loss; M, methylated; ML, monoallelic loss; ND, not determined; U, unmethylated; WT, diploid.
Bold denotes SS patients derived from the data set already published in Caprini et al.5
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Immunohistochemistry
Parafﬁn-embedded skin tissues from SS/MF patients were selected from the
ﬁles of IDI Pathology. Specimens were classiﬁed according to the EORTC
classiﬁcation.1 PTEN used 1:100 (clone 6H2.1) and pAKT used 1:15 (clone
14-5) (Dako, Fort Collins, CO) were retrieved in pH9 and high pH buffer
(Dako), respectively, by incubation in a bath at 96°C for 30 minutes.
Samples were then revealed by the streptavidin-biotin peroxidized labeling
method and DAB staining. Sections were counterstained with hematoxylin
and mounted with aqueous mounting media.
Statistics
Statistical analyses were carried out with the software GraphPad PRISM 5
(GraphPad Software Inc., La Jolla, CA). Differences were evaluated with
2-tailed Student test and a Pearson correlation test. P < .05 was considered
signiﬁcant.
Results
PTEN is frequently deleted but not mutated in SS
The Affymetrix 10K and SNP6.0 arrays were used to investigate
the copy number (CN) status of the PTEN locus in 68 samples
derived from 44 SS patients and 3 cell lines (Table 1). The SS group
was composed of 27 SS cases available of 28 cases previously
investigated from our laboratory with the SNP-10K array and
oligonucleotide–comparative genomic hybridization array (aCGH).5
The clinical features of the new enrolled 17 SS are shown in
supplemental Table 1. The monoallelic loss of PTEN has been ob-
served in 16 of 44 SS patients (36%); in 3 cases (32, 39, and 53),
PTEN was heterozygously deleted in both the T1 and T2 follow-up
samples, whereas in 2 cases (61 and 64), the loss became homozygous
in the second follow-up, suggesting that this aberration may be
correlated with the tumor progression. A biallelic deletion of
PTEN was also observed in the HH cell line and conﬁrmed by
Western blotting analysis (Figure 1). The SNP mapping arrays also
enable unravel uniparental disomy (UPD) events (ie, regions of
LOH within a normal diploid CN state); these abnormalities may be
explained by a loss of genetic material followed by a re-duplication
of the remaining alleles. We found that patient SS28 exhibited UPD
encompassing the PTEN locus.
Altogether, we found a hetero/homozygous loss of PTEN in 16
of 44 SS cases (36%) and in all of the cell lines we analyzed,
whereas 1 SS patient showed a UPD event.
We validated the SNP arrays performing genomic qRT-PCR on
27 SS samples (see Methods for details). Using the relative standard
curve methods, we obtained FC values ranging from 0.72 to 1.2 for
SS patients, displaying a normal PTEN diploid status (n 5 14); FC
values ,0.72 were observed in all heterozygous PTEN-deleted
samples (n 5 11), whereas for SS61 T2 and SS64 T2, showing
a homozygous deletion of PTEN, we calculated a FC of 0.09 and
0.26, respectively (Table 1). CTCL cell lines were not validated
because endogenous control genes used to normalize genomic
qRT-PCR were affected by chromosomal imbalances.
Because PTEN is frequently also inactivated by nucleotide mu-
tation, we decide to perform a target re-sequencing of PTEN coding
exons. Twenty-ﬁve samples (21 patients plus 4 follow-ups from
SS60, SS63, SS50, and SS23) were subjected to deep-sequence
analysis, which did not reveal any mutation, indicating that this
mechanism does not occur in SS. Also, the sequence of SS28
carrying UPDwas wild-type, indicating that this genetic alteration
does not affect the gene sequence.
In addition to genetic deletion, PTEN can be transcriptionally
silenced by the hypermethylation of the promoter region.Methylation-
speciﬁc PCR performed on 25 patients and 3 cell lines led us to
exclude that PTEN is inactivated by this mechanism in SS
(Table 1).
PTEN abundance can be modulated by several miRNAs.24
Recently the PTEN pseudogene, PTENP1 showing an extensive
sequence similarity to PTEN, has been described as a modulator
of the interaction between PTEN, messenger RNA (mRNA), and
miRNAs. By this mechanism, it can protect PTEN from miRNA
downregulation and exert a tumor suppressor role.25 The PTENP1
locus at chromosome 9p13.3 is selectively lost in human cancer.25
In contrast to other malignancies, we observed a PTENP1deletion
only in 3 of 44 patients (2%) and in the Hut78 and H9 cell lines
(Table 1), thus indicating that PTENP1 is not under a strong
genomic selective pressure in SS.
PTEN is commonly downregulated in SS
To establish whether the genomic loss of PTEN was also reﬂected
by the loss of PTEN expression, we analyzed the mRNA level in
enriched neoplastic CD41cells of 2 patients with a homozygous
deletion (SS61T2 and SS64 T2), 5 patients with a heterozygous
deletion (SS36, SS53, SS55, SS57, SS58), and 10 patients with
a wild-type PTEN status (SS30, SS40, SS41, SS43, SS45, SS50,
SS60, SS62, SS63, SS65) vs sorted CD31/CD41 peripheral
lymphocytes from 5 healthy donors (HDs). qRT-PCR results
showed a signiﬁcant PTEN downregulation in all SS individuals
analyzed (FC mean value, 0.51) vs HDs (P 5 .038). Moreover,
we observed a decreased PTEN expression in SS patients showing
a PTEN hetero (1/2) and homozygous (2/2) deletion (FC mean
value, 0.24) when compared with those associated to a PTEN
wild-type (1/1) status (P 5 .044), indicating that the PTEN
mRNA level is dependent on its genomic status. However, we
observed that SS41, SS60, and SS62, with a PTEN1/1 genotype,
expressed a very low mRNA level, suggesting that additional
PTEN-inactivating mechanism(s) may act at the transcriptional
level (Figure 2A).
Next, we evaluated the PTEN protein level by Western blotting
analysis of puriﬁed CD41 neopastic cells from 19 SS patients and
5 HDs. The results revealed that SS samples showed a signiﬁcantly
decreased PTEN protein level of 0.17 6 0.15 compared with HDs
(0.46 0.01) (P5 .04). Moreover, in accordance with mRNA data,
we found that PTEN abundance is signiﬁcantly inﬂuenced by the
gene dosage, as demonstrated by the mean of PTEN densitometric
values of 0.2 6 0.13, observed in PTEN1/1 cases (n 5 9) vs
0.09 6 0.08 values associated with PTEN1/2 and PTEN2/2 samples
(n 5 9) (P 5 .02), whereas a value of 0.59 was associated to SS28
coherently with a functional PTEN diploid status potentially restored
by a UPD event. As expected, no PTEN protein was detected in the
SS61 T2 sample with homozygous deletion of PTEN (Figure 2B).
Figure 1. PTEN protein in CTCL cell lines.Western blotting analysis revealing the
PTEN level in CTCL cell lines. No PTEN protein is detected in HH cells, in agreement
with their PTEN2/2 status.
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Overall, these results indicate that mRNA level is consistent with the
PTEN protein abundance observed.
PTEN is regulated in vitro by multiple miRNAs and miR-106b
correlates with PTEN expression in vivo
We next asked whether miR-21, miR-106b, miR-214, and miR-486,
all correlated with a worst SS prognosis26 and already validated to
target PTEN in many cancers,27-30 were also able to regulate PTEN
level in our system. Using a loss or gain of function approach, we
ﬁrst overexpressed them in the H9 cell line in which PTEN protein is
well detectable (Figure 1). After 48 hours, we revealed by qRT-PCR
an overexpression of all miRNAs investigated (supplemental
Figure 1); concurrently, we observed a reduction in the PTEN level
of 40%, 60%, and 40% after pre–miR-21 (n 5 6), pre–miR-106b
(n 5 6), and pre–miR-486 (n 5 3), respectively (Figure 3A-B),
whereas pre–miR-214 did not show a consistent downregulation of
PTEN (data not shown). qRT-PCR analysis revealed that only
pre–miR-106b was able to reduce about 80% of PTEN transcript,
whereas all other miRNAs did not inﬂuence but rather enhanced it.
This latter observation might be explained by PTENP1 mRNA co-
expression that, different from PTEN, is targeted by miR-106b but
also by miR-214 and miR-486, preserving PTEN from degradation
(supplemental Figure 2). In light of these results, we correlated
PTENP1 expression with miRNAs levels and PTEN mRNA also in
vivo without ﬁnding any signiﬁcant relationship among these genes
(data not shown).
Because H9 express high levels of miR-21 and miR-106b (sup-
plemental Figure 1), we next tested whether knockdown of these
miRNAs was able to enhance PTEN expression. Western blotting
analysis of anti–miR-21 (n 5 3) and anti–miR-106b (n 5 3)
transfectants revealed an increase in the PTEN level of 1.66 0.9 and
1.86 0.25 FC, respectively, conﬁrming the ability of these miRNAs
to modulate in vitro PTEN in the CTCL cell line (Figure 3B). Finally,
because miRNAs can affect gene expression via translational inhibi-
tion and/or the target mRNA degradation mechanism, we investigated
the correlation between miRNAs and PTEN mRNA levels in sorted
CD41 neoplastic cells. To better evaluate the degradation effect of
miRNAs on PTEN transcripts, excluding an mRNA reduction
because of mono or biallelic deletion of the PTEN gene, we focused
our attention on 9 available SS patients associated with a PTENwild-
type status. In agreement with the miR-106b ability to target PTEN
mRNA in vitro, we found a signiﬁcant inverse relationship between
miR-106b and PTEN mRNA levels (R 5 20.79, P 5 .01 Pearson
correlation test) (Figure 4C-D); 4 samples, also analyzed for protein
expression, conﬁrmed this result (R520.96, P5 .04) (Figure 4E).
Furthermore, in the PTEN target, deep-sequencing approach, the
4 recognized miR-106b binding regions within 39UTR were in-
cluded. The results revealed the transition c.*1123 G.A within the
miR-106 target site occurring in patient SS23 T1 and T2 samples. The
variation appears in 50% of the sequence reads, suggesting it may
represent a rare polymorphismwhose biological signiﬁcance, however,
could not be further investigated because of the unavailability of the
corresponding RNA.
Hence, these data support the notion that, in addition to genomic
losses, PTEN is also downregulated in SS by multiple miRNAs both
in vitro and in vivo.
Low level of PTEN does not enhance the AKT kinase activity in
circulating SS cells
Having demonstrated the low PTEN abundance in SS cells, we next
sought to establish whether this deﬁciency could activate the PI3/AKT
pathway. For this purpose, we evaluated by Western blotting the
Figure 2. PTEN levels measured in SS patients. (A) qRT-PCR analysis of PTEN performed in 17 SS patients. The PTEN mRNA level was calculated for each SS patient
relatively to a reference pool consisting of 5 healthy controls (black bar). The bottom portion indicates the percentage of clonal TCR vb1 cells within the CD41 fraction and the
PTEN status represented as wild type (1/1), heterozygous deletion (1/2), and homozygous deletion (2/2). Samples were measured in 2 independent experiments
performed in triplicate. (B) Western blotting analysis of PTEN in the purified CD41 cells of 19 SS individuals grouped by PTEN1/1, 1/2, and2/2, and UPD genomic status.
Two representative HDs of the 5 analyzed are shown in the figure. Because of the timing of patient recruitment, the gels were run at separate times and the lanes were
composed for the figure.
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basal AKT amount of CD41-sorted cells from 5 SS patients and
5 HDs. Our results demonstrated a slight, although not signiﬁcant,
decrease of AKT protein in SS samples when compared with HDs
(2.2 6 0.95 vs 2.61 6 0.68) (Figure 4A). To further clarify this
aspect, we investigated the phospho-Akt level of puriﬁed CD41
cells from 14 SS patients vs 5 HDs using an antibody that recog-
nizes AKT at Ser473. SS cases showed a signiﬁcantly low amount
of phosphorylated/activated AKT vs control (0.12 6 0.16 vs
0.39 6 0.12; P 5 .003), suggesting that the majority of circulating
SS cells are quiescent or low-cycling cells (Figure 4B). The only
exception is represented by SS65 and SS67 (showing pAKT values
of 0.44 and 0.53, respectively) that seem to have an active
canonical survival/proliferation pathway mediated by PI3K/AKT.
PTEN and pAKT are detectable in SS skin biopsies
We then evaluated the PTEN expression also in skin-homing SS
cells, and using IHC analyses we investigated 24 SS and 10 MF
skin biopsies. Parafﬁn-embedded cell blocks generated from
Hut781/2 PTEN and HH2/2 PTEN cell lines were used as positive
and negative controls, respectively, for PTEN immunoreactivity
(Figure 5A,E). In agreement with our biochemical data, we ob-
served a very weak immunostaining, at the cytoplasmic and nuclear
levels, in 13 of 24 SS cases (54%) associated with 5% to 30% of
malignant lymphocytes (Figure 5B-C), whereas the remaining 11
samples (46%) were consistently negative. Conversely, a moder-
ate nuclear and cytoplasmic PTEN expression was observed in 6
of 10 (60%) of MF coupled with 5% to 30% of neoplastic cells
(Figure 5D).
Finally, to address the question of whether SS skin resident cells,
similarly to circulating neoplastic counterparts, also display an
inactive AKT pathway, we analyzed by IHC 21 SS skin as well as
psoriasis used as a positive control. In SS cases, pAKT immuno-
reactivity was detected at the cytoplasmic level, in 21 of 21 (100%)
samples, andwas associatedwith 5% to 40%ofmalignant lymphocytes
inﬁltrating the dermis (Figure 5F-G). Interestingly, we noted that
pAKT was strongly expressed in actively duplicating SS cells
(Figure 5H). We also found pAKT (Ser473) immunostaining in
psoriatic epidermis keratinocytes as already described,31 but
we did not detect pAKT staining in healthy skin (supplemental
Figure 3).
These ﬁndings show a different behavior of SS cells depending on
the district localization (Table 2). Overall, these data indicate that,
coherently with genomic and expression data, PTEN is downregulated
in SS skin resident cells vs MF used as a reference. Furthermore,
different from circulating SS cells, we found a moderate percentage
Figure 3. PTEN regulations by miRNAs in SS patients. (A) Densitometric values calculated as PTEN/actin showed a PTEN protein reduction in pre–miR-21, pre–miR-
106b, and pre–miR-486 transfected H9 cells vs fluorescein-scrambled oligo used as control. Data are given as mean6 SD from 9 independent experiments (*P5 .02, **P5 .006).
(B) Western blotting analysis performed in pre-miRNAs and anti-miRNAs transfected H9 cells showed a reduction or increase in PTEN protein level, respectively. Two of 9
representative electrophoretic patterns are shown. (C-D) A significant inverse relationship between PTEN and miR-106b was observed comparing their mRNA levels
measured by qRT-PCR in 9 SS patients with a 1/1 PTEN status (R5 20.79, P 5 .01 for Pearson correlation test). (E) An inverse correlation between PTEN protein levels
and miR-106b was also observed in 4 samples simultaneously analyzed by Western blotting and qRT-PCR (R5 20.96, P 5 .04 for Pearson correlation test).
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of skin-inﬁltrating neoplastic lymphocytes constantly expressing
pAKT in all samples.
Discussion
PTEN is one of the most commonly mutated and deleted tumor
suppressors in human cancer. Despite several studies identifying
the PTEN locus variously affected by genetic deletion in CTCL,3-5
its involvement in this disease has not been fully investigated.
Here, we have performed an extensive study on PTEN status in a
large cohort of SS samples to deﬁne the level of PTEN deregulation.
In line with its tumor-suppressive activity, we found that PTEN
is lost in 36% of SS cases examined, indicating that its depletion
represents a crucial step in SS pathogenesis that, conversely to MF,10
seems to not be associated with the late phase of disease because
PTEN loss frequency is similarly observed in early (37%) and late
(33%) samples analyzed before and after 12 months from diagnosis,
respectively, thus suggesting that this event occurs during the
initial phase of disease to be maintained in tumoral progression
(data not shown). The deep sequencing performed on the same
SS patient group did not demonstrate any mutations within the
PTEN coding region.
A PTEN downregulation, both at the mRNA and the protein
level, was observed in almost all of the samples we analyzed. In-
vestigating other possible regulatory mechanisms, we demonstrated
that neither PTENP1 pseudogene nor a promoter hypermethylation
process are active in SS, whereas we found that miR-21, miR-106b,
and miR-486 are able to modulate in vitro PTEN level, and miR-106b
also displays a signiﬁcant inverse relationship with PTEN abun-
dance in vivo, indicating that this miRNA is deeply involved in
SS pathobiology.
Experiments of genetic manipulation in mice have demon-
strated that subtle reduction of PTEN levels have critical effects
for tumorigenesis.19 In view of these ﬁndings, we can speculate
that PTEN genomic loss, when accompanied by miRNA down-
regulation, might be more effective at promoting tumorigenesis
in SS cells. This hypothesis also seems to be supported by the
worst prognosis of SS22, SS30, SS32, SS39, SS43, and SS45
patients in which miR-21, miR-106b, and miR-486 were co-
overexpressed26; in addition, mouse models overexpressing PTEN
targeting miR-17-92 cluster (miR-106b-25 homolog) develop T-cell
lymphoma.32
PTEN expression and localization was also evaluated by IHC.
Although we were not able to compare IHC and SNP array results
because the samples were not concurrently analyzed, we detected a
very faint or absent PTEN immunoreactivity in all cases examined,
in good agreement with Western blotting results. Similarly to
peripheral T-cell lymphomas,33 we observed a nuclear and cyto-
plasmic localization of PTEN within the SS cells. Nuclear PTEN is
found in cells arrested at the G0/G1 phase,34 whereas proliferating
cells mainly show cytoplasmic PTEN.35 Thus, our ﬁndings suggest
that SS cells are not quiescent but they can grow within a cutaneous
background. Consistent with this hypothesis, we found AKT activa-
tion in SS cells that inﬁltrate the skin but not in the circulating
ones, suggesting that skin microenvironment stimulates SS cells
through direct-cell interactions and/or growth factor stimulation.
A hypothesis, that PTEN reduction can amplify pathways induced
by SS cell adhesion to the cutaneous milieu, thus promoting
growth/survival of skin-inﬁltrating malignant lymphocytes, is
supported by various ﬁndings: ﬁrst, in the skin, SS cells interact
with Langerhans cells in the intraepidermal Pautrier micro-
abscess; second, SS cells coexpress skin homing receptors as
CLA and CCR4 that speciﬁcally bind adhesion molecules present
on endothelial cells of the skin, such as E-selectin and TARC36;
and third, SS cells that migrate via chemokines,20,37 induce PI3K
pathway, leading to AKT activation.38
The SS genome is characterized by a high chromosomal insta-
bility with recurrent gains, losses, or rearrangements.4,5 Genome-
wide array analyses have identiﬁed genes that might contribute to
genetic instability of SS such as TP5339; this gene is of particular
importance because it is located at chromosome 17p13.3–17p13.1,
a region that shows a high frequency of deletion in SS ranging
from 71% to 75%.4,5 PTEN controls the P53 stability via MDM2
and interacts with p53, enhancing its acetylation and its DNA
binding ability.39,40 Alternatively, p53 positively controls the
transcription of PTEN.41 Because PTEN also plays a crucial role
Figure 4. Basal and phospho-AKT levels measured in SS patients. (A) Western blotting analysis for AKT performed in sorted CD41 lymphocytes from 5 SS patients. Two
representative HDs of 5 patients analyzed are shown. (B) Western blotting analysis for phospho-AKT of sorted CD41 lymphocytes from 14 SS patients. Two representative
HDs of 5 patients analyzed are shown. Because of the timing of patient recruitment, the gels were run at separate times and the lanes were composed for the figure.
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in genomic stability,42 we can speculate that reduced PTEN abun-
dance in SS could perturb the positive regulatory relationship
between PTEN and p53, contributing to the chromosomal alterations
frequently observed in SS.
SS cells arise from central memory T lymphocytes,43 cells able
to remember a pathogen persisting for as long as the lifetime of
individuals via long-term homeostasis, a condition that implies a
great resistance to both spontaneous and FAS-induced apoptosis.44
Recent studies have demonstrated that members of the Forkhead
box (FOXO) family of transcription factors are important regulators
of quiescence and longevity, playing critical roles in the development
and function of memory subsets.45 Akt directly phosphorylates
and inactivates members of the FOXO family, detaining them to
cytoplasm.46 Interestingly, central memory T lymphocytes express
high levels of phosphor-FOXO3a,47 maintaining in this way low
levels of proapoptotic and cell cycle arrest FOXO3a target genes
like FAS ligand, Bim, and p27, which are downregulated in SS.48-50
Altogether, this evidence strongly suggests that PTEN may enhance
the apoptotic resistance of SS cells via FOXO3a, thus contributing
with other genetic hits to their malignant expansion.
In conclusion, our data demonstrate that in SS, similarly to other
malignancies, genetic deletion of the PTEN locus is highly recurrent.
However, other deregulating mechanisms, such as abnormal expres-
sion of miRNAs, may inﬂuence PTEN expression; particularly,
miR-106b shows a signiﬁcant inverse relationship with PTEN level
not only in vitro, but also in vivo. Finally, our results also provide
evidence that low PTEN level does not activate AKT in circulating
SS cells but, alternatively, it activates AKT in skin-inﬁltrating SS
cells, indicating that skin milieu may strongly contribute to the SS
pathogenesis and progression. To our knowledge, this is the ﬁrst
Figure 5. Immunohistochemistry of PTEN and
pAKT performed in SS and MF skin biopsies. (A)
Hut78 as a positive control for PTEN (original magnifica-
tion 340/0.7 numerical aperture); (B-C) PTEN immu-
noreactivity in SS skin (B, original magnification
320/0.6 numerical aperture; C, original magnification
310/0.3 numerical aperture); (D) PTEN immunoreac-
tivity in MF (original magnification 320/0.6 numerical
aperture); (E) HH as a negative control for PTEN (original
magnification 340/0.7 numerical aperture); (F-G) pAKT
immunostaining associated with the cytoplasm of
keratinocytes and scattered malignant lymphocytes
(original magnification 320/0.6 numerical aperture);
and (H) strong pAKT positivity associated with the
cytoplasm of SS cells and particularly with actively
dividing mitotic cells (original magnification 340/0.7
numerical aperture). Digital images were acquired with
an AxioCam MRc5 camera (Zeiss) and an Axioskop2
microscope (Zeiss).
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study to fully explore the status of PTEN in SS, shedding light on
the mechanisms of its malfunctioning in this malignancy and
unveiling information of potential clinical importance.
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